DDInter458 DDInter1021
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lurasidone
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Cyclosporine {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Cyclosporine {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is downregulated by {v} (Compound) Digitoxin
Digitoxin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Cyclosporine {u} (Compound) downregulates {v} (Gene) CDC45
CDC45 {u} (Gene) is downregulated by {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Cyclosporine {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Cyclosporine {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Lurasidone
Lurasidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Cyclosporine {u} (Compound) downregulates {v} (Gene) MELK
MELK {u} (Gene) is upregulated by {v} (Compound) Sitagliptin
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Cyclosporine {u} (Compound) downregulates {v} (Gene) DNMT1
DNMT1 {u} (Gene) is bound by {v} (Compound) Procainamide
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Cyclosporine {u} (Compound) treats {v} (Disease) rheumatoid arthritis
rheumatoid arthritis {u} (Disease) is palliated by {v} (Compound) Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound) and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Cyclosporine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Cyclosporine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is downregulated by Digitoxin (Compound) and Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Cyclosporine (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Cyclosporine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Cyclosporine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Lurasidone (Compound) and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Cyclosporine (Compound) downregulates MELK (Gene) and MELK (Gene) is upregulated by Sitagliptin (Compound) and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Cyclosporine (Compound) downregulates DNMT1 (Gene) and DNMT1 (Gene) is bound by Procainamide (Compound) and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Cyclosporine (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is palliated by Lidocaine (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide